February 8, 2024Open Access

Ashwagandha

XLXin Yi LimMinistry of Health JBJoanne BarnesUniversity of Auckland

Key Points

Key points are not available for this paper at this time.

Abstract

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)

KI fragen

Bookmark

View Full Paper

Cite This Study

Lim et al. (Thu,) studied this question.

synapsesocial.com/papers/68e7b7dcb6db64358770e626 https://doi.org/https://doi.org/10.1071/hc23172

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda2020 · 155 citations
2Ashwagandha (Withania somnifera) for the treatment and enhancement of mental and physical conditions: A systematic review of human trials2021 · 57 citations
3Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta‐analysis of randomized controlled trials2022 · 71 citations
4Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial.2019 · 52 citations
5Adjunctive Use of a Standardized Extract of <em>Withania somnifera</em> (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia2018 · 72 citations

KI fragen

Bookmark

View Full Paper